RapImmune vs. allergy shots
RapImmune and traditional allergy shots both work by building lasting tolerance to environmental allergens, and what separates them is how long that takes and how many visits it costs you. RapImmune is three ultrasound-guided injections over about eight weeks. Allergy shots are roughly 100 injections over three to five years, and in a Florida Medicaid claims cohort 84% did not complete the three years needed for lasting benefit.
Both build tolerance to the same environmental allergens, and both are run by the same physician in the same clinic. What separates them is how the dose is delivered, and what that does to the calendar.
BEFORE THE TABLE
Allergy shots are the long-established option with good published evidence behind them. RapImmune is newer, faster and uses FDA approved allergen extract but takes an off-label delivery route: direct to the lymph node. Allergenix offers RapImmune rather than allergy shots, and this page sets out why — with the case for shots left standing.
Two paths to allergy relief. Very different economics.
Traditional allergy shots (subcutaneous immunotherapy, or SCIT) have been the gold standard for decades — and they work. But the 3–5 year commitment through commercial insurance carries costs that many patients don't see until they're deep into treatment. RapImmune® delivers allergy immunotherapy through a fundamentally different approach.
Intralymphatic immunotherapy
Total program fee. All-inclusive. No ongoing charges.
- Duration
- About 3 months
- Total visits
- 3 injections*
- Insurance required?
- No
- Facility fees
- $0
- Deductible applies?
- No
- Surprise bills
- None
- Completion rate
- ~100%1
*A booster injection may be given if clinically indicated.
Allergy shots, 3–5 year course
Patient out-of-pocket over 5 years. Varies by plan type.
- Duration
- 3–5 years
- Total visits
- ~109+ over 5 years
- Insurance required?
- Yes
- Facility fees
- $0–$108+/visit6
- Deductible applies?
- Yes, resets annually
- Surprise bills
- Possible
These allergy shot figures are for treatment through commercial insurance, which is how most people receive them. Allergenix does not offer traditional allergy shots — this comparison is here because it is the question most people arrive with, not because both are on the menu.
Eleven facts, both columns
| RapImmune®Intralymphatic · ILIT | Allergy shotsSubcutaneous · SCIT | |
|---|---|---|
| Number of clinic visits | 3 | 100+ injections |
| How long the program runs | About two months | Three to five years |
| Where the dose goes | Into a lymph node | Under the skin |
| Ultrasound guidance | Every injection | Not used |
| Injections per session | 1–2 | 1 |
| Allergens treated | Pollen, dust mites, pets, molds | Pollen, dust mites, pets, molds |
| Program fee | $3,500 total | $4,400–$6,000 out of pocket, through insurance |
| Follow-up visits | Included | Billed as they occur |
| Serums custom-blended for you | Yes | Yes |
| FDA status | Extracts are FDA-approved; the injection into the lymph node is not | Long-established standard of care |
| Availability locally | As of 2026, we are not aware of another practice in Iowa or much of the upper midwest offering ultrasound-guided intralymphatic immunotherapy | Widely available |
What do traditional allergy shots (SCIT) actually cost a patient over 5 years?
Published claims data reveal costs that go far beyond the sticker price. Here's what a commercially insured patient can expect to pay out-of-pocket for a complete 5-year course of allergy shots — broken down by the numbers.
| Cost category | PPO / HMO plan | High-deductible plan | Source |
|---|---|---|---|
| Per-visit copay / out-of-pocketAverage $32/visit across plan types | $40–$50/visit | Full negotiated rate until deductible met | Tkacz 2021 |
| Build-up & transition visits (Year 1)~41 visits per recommended AAAAI protocol: 1–2×/week for ~5 months, then every other week, then monthly by ~month 10. (Note: Blume et al. observed 27.3 build-up visits/year in practice, likely reflecting missed appointments.) | $1,640–$2,050 | $2,000–$3,200+ | AAAAI protocol; Blume 2015 |
| Maintenance visits (Years 2–5)~17 visits/year × 4 years = 68 visits | $2,720–$3,400 | $2,176–$4,000+ | Blume 2015 |
| Initial consultation & testing~20% had consultation costs >$1,000 | $100–$500 | $300–$1,000+ | Mao 2019 |
| Annual deductible contributionAvg $1,787 individual; resets each January. Testing and procedures apply toward deductible before coinsurance begins. | Copays apply regardless of deductible; testing/procedures subject to deductible first | $2,418/yr avg — all services at full negotiated rate until met | KFF 2024 |
| Hospital facility fees, where applicableApplies at hospital-owned practices only | +$0–$22/visit (patient share) | +$0–$108/visit (until deductible) | Sen 2022; Neprash 2015 |
| Estimated 5-year patient out-of-pocket (direct) | $4,400–$6,000 | $5,500–$8,500+ |
Why the range? Your actual cost depends on your plan type (PPO, HMO, HDHP), whether your allergist practices in a hospital-owned clinic vs. independent office, your specific deductible and coinsurance terms, and how many years you continue treatment. Published data consistently show that total payment for the same service in a hospital outpatient department is 145% higher than in a physician's office, with patient out-of-pocket costs 109% higher.6
Time is a cost. Here's how much traditional allergy shots (SCIT) take.
Dollar figures tell only part of the story. Published research quantifies the enormous time burden of traditional allergy shots — time that compounds over years of treatment. All three figures below refer to traditional allergy shots (SCIT) through insurance.
About the “4 hours” figure: A survey of 106 adult allergy shot patients and 191 caregivers found a median of 4 hours of work missed per injection visit. This reflects total work disruption, not literal time in the allergist’s office. A mid-afternoon appointment means leaving work early, driving to the clinic, receiving the injection, completing the required 30-minute observation, and driving back — effectively losing the second half of a workday. Many employers don’t allow partial-hour leave, so the practical impact is a half-day missed. Your actual time impact will depend on how close you live to your allergist’s office, your work schedule flexibility, and your employer’s leave policies.9
~41 visits in Year 1 (build-up through monthly maintenance) + ~17 visits/year × 4 years. That’s 118+ hours in the car, waiting room, and clinic — plus an estimated 436 hours of lost work productivity.49
3 ultrasound-guided injections at Allergenix over ~8 weeks. All consultations, follow-ups, and oversight included in one transparent fee. A booster injection may be given if clinically indicated.
Adding it up. At the published national average of $29/visit in travel costs over 109 visits, a traditional allergy shot patient spends approximately $3,161 in ancillary expenses alone — nearly matching the entire RapImmune® program fee before you count a single copay. Ancillary costs may be lower in markets with free parking and no tolls.9
The most expensive allergy treatment is the one you don't finish
Immunotherapy only works if patients complete the course. A minimum of 3 years is required for lasting benefit. The published completion rates tell a sobering story about traditional SCIT — and reveal one of RapImmune®'s most important advantages.
Claims-based studies, which capture every patient who stops rather than only those who stay in follow-up, report the lowest completion figures. In a Florida Medicaid claims cohort of 3,048 children, 84% did not complete three years of immunotherapy, and approximately 53% stopped inside the first year — before any disease-modifying benefit could accrue. Only 16% completed the three-year course. Published adherence figures vary widely across studies because definitions are not standardized; the AAO-HNS 2024 clinical practice guideline reports a range spanning 7% to 97% and concludes that SCIT persistence and adherence are generally poor.310
Cost and coverage remain the leading stated reason for stopping. In a survey of 555 patients who discontinued allergy shots, 40% cited insufficient insurance coverage of allergen extracts and injection visits, while side effects accounted for only about 1.5% of discontinuations.10
The most telling figure comes from a setting where cost is removed entirely. In a military healthcare system where patients had zero out-of-pocket costs, only 34% completed three or more years — evidence that the barrier is the visits themselves, not only the money.7
In published intralymphatic immunotherapy (ILIT) clinical trials — the approach used in the RapImmune® program — virtually every patient completes the 3-injection protocol. When treatment takes 3 visits instead of 100+, completion is no longer a barrier to lasting results.1
A note on data sources: The ILIT completion rates above come from clinical trials with enrolled, consented participants, while the allergy shot completion rates come from real-world insurance claims databases tracking tens of thousands of patients. These are not perfectly parallel comparisons. However, the fundamental point remains: a 3-visit protocol inherently eliminates the logistical, financial, and time barriers that drive the high attrition rates observed in multi-year allergy shot programs — regardless of the study setting.
The total economic burden: direct + indirect costs
When you combine the direct out-of-pocket expenses with the indirect costs of time, travel, and missed productivity, the full economic comparison becomes clear.
| Category | RapImmune | Allergy shots, 5 years, PPO |
|---|---|---|
| Direct medical out-of-pocketCopays, coinsurance, deductible | $3,500 (all-inclusive) | $4,400–$6,000245 |
| Travel & ancillary costs$29/visit, national avg. Published per-visit median (parking $10, tolls $9, other $10); five-year total extrapolated across the protocol visit count. May be lower in some markets. | ~$87 (3 visits) | $3,1619 |
| Lost work productivity4 hrs/visit × $22/hr Iowa median wage. Published per-visit median of work missed (Tankersley 2021); five-year total extrapolated across the protocol visit count and valued at the Iowa median hourly wage (BLS). | ~$264 | $9,592911 |
| Facility fees$0 at independent clinics; $22/visit patient share at hospital-owned | $0 | $0–$2,3986 |
| Risk of wasted investmentProbability of an incomplete course | ~0%1 | 66–84%37 |
| Estimated total economic burden | $3,851 | $17,153–$21,151 |
On methodology
The traditional allergy shot ranges reflect conservative estimates from published peer-reviewed data. The visit count of about 109 over five years follows the recommended clinical protocol: one to two injections a week during build-up for about five months, tapering to every other week, then monthly maintenance for three to four years. Lower bounds assume a PPO plan at an independent, non-hospital clinic. Upper bounds reflect the top of the PPO out-of-pocket range plus hospital facility fees; they do not add high-deductible cost-sharing, which would raise the total further. Per-visit direct costs and work time missed are published survey medians; the five-year totals shown are extrapolated by applying those per-visit figures across the protocol visit count.
On facility fees
The $0–$2,398 range reflects the fact that independent clinics charge no facility fee, while hospital-owned outpatient clinics charge a separate facility fee averaging $108/visit in the commercial market. At 20% coinsurance, that’s ~$22/visit in additional patient OOP × 109 visits = $2,398. Not all allergists practice in hospital-owned settings — in the Des Moines area, for example, allergists currently practice in independent settings. But nationally, hospital-owned outpatient clinics are increasingly common, and patients should understand this cost differential.
On lost work productivity
The $9,592 figure uses the published median of 4 hours of work productivity lost per injection visit from Tankersley et al. (2021) multiplied by the Iowa median hourly wage of approximately $22/hr (U.S. Bureau of Labor Statistics). This represents total workday disruption — not literal time in the office. A mid-afternoon appointment may require leaving work 30–60 minutes early, plus 25 minutes of travel each way, check-in, injection, and 30-minute observation, effectively losing the second half of a workday. Your actual impact will vary with drive distance, work flexibility, appointment timing, and your individual wage.
On completion rates
Adherence definitions are not standardized across the literature, so figures are not strictly comparable. Claims-based studies capture every dropout, including patients lost to the payer, and report the lowest rates: Hankin et al. (2008) reported that 84% completed less than three years of immunotherapy and approximately 53% completed less than one year, in a Florida Medicaid cohort of 3,048 children. One limit on that figure: persistence is measured by claims duration rather than protocol completion. Pediatric Medicaid persistence is also strongly influenced by coverage continuity and should not be generalized to commercially insured or adult populations; it is the low anchor of the range, not a typical value. Single-centre chart studies, which count only actively followed patients, report higher figures — Di Bona et al. (2020) 43.5% and Borg et al. (2020) 57% at three years. Mendoza et al. (2023) found 34% completed three or more years even with zero out-of-pocket costs. The AAO-HNS 2024 guideline reports an overall adherence range of 7% to 97% and concludes SCIT persistence and adherence are generally poor. The 66–84% incomplete range shown above spans the discrete U.S. cohort results, 16% to 34% completion.
A different approach to allergy relief
RapImmune® is a premium, physician-delivered intralymphatic immunotherapy (ILIT) program. Instead of repeated injections into the arm over years, small doses of allergen are placed directly into a lymph node under high-definition ultrasound guidance — targeting the immune system where tolerance is built.
The entire program consists of 3 ultrasound-guided injections over approximately 8 weeks, with all consultations, personalized lymphatic mapping, and follow-up care included in one transparent fee. A booster injection may be given if clinically indicated.
RapImmune® is designed for patients with environmental allergies — pollen, dust mites, pets, and molds — who want rapid relief with evidence of sustained benefit in published clinical trials, without the 3–5 year commitment of traditional allergy shots.
Allergenix is currently the only practice in Iowa offering intralymphatic immunotherapy.
A note on the evidence: ILIT is a newer immunotherapy approach that uses FDA-approved allergen extracts delivered via an off-label route (intralymphatic injection). The most comprehensive systematic review and meta-analysis to date pooled data from 15 randomized trials involving 582 patients, with cumulative enrollment across all published ILIT trials now estimated at approximately 800 participants. The evidence base is smaller and more recent than that supporting traditional allergy shots, which have been studied extensively for over a century. RapImmune® uses only FDA-approved allergen extracts. Dr. Stanga discusses the clinical evidence, expected outcomes, and limitations of both approaches during every consultation so patients can make a fully informed decision.1
References
- Wang W, et al. Evaluation of safety, efficacy, and compliance of intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis of 15 RCTs (582 participants). Int Arch Allergy Immunol. 2023. / Liu L, et al. Is intralymphatic immunotherapy effective and safe for allergic rhinitis?: a meta-analysis of 11 RCTs (406 participants). Medicine. 2024. / Hoang MP, et al. Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis (483 participants). Rhinology. 2021. / Werner MT, Bosso JV. Intralymphatic immunotherapy for allergic rhinitis: a systematic review and meta-analysis of 17 trials. Allergy Asthma Proc. 2021. / Jiang S, et al. Evaluation of intralymphatic immunotherapy in allergic rhinitis patients: a systematic review and meta-analysis of 13 studies (454 participants). Mediators Inflamm. 2023.
- Tkacz J, et al. Real-world cost and utilization of allergy immunotherapy in a commercially insured U.S. population. Curr Med Res Opin. 2021;37(6).
- Hankin CS, Cox L, Lang D, Levin A, Gross G, Eavy G, Meltzer E, Burgoyne D, Bronstone A, Wang Z. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol. 2008;121(1):227–232. doi:10.1016/j.jaci.2007.10.026. PMID 18206509. Retrospective Florida Medicaid claims analysis, 1997–2004: of 102,390 children with newly diagnosed allergic rhinitis, 3,048 (3.0%) received immunotherapy; approximately 53% completed less than 1 year and 84% completed less than 3 years. / Di Bona D, et al. 30-year retrospective cohort, 2,200 patients: 43.5% completed 3 years. Respir Med. 2020. / Borg M, Løkke A, Hilberg O. Nationwide Danish study: 57% at year 3. Respir Med. 2020. / Mao EJ, et al. (2019) — 15.1% inconsistent use in 131,493 SCIT patients.
- Year 1 visit count (~41) based on the AAAAI/ACAAI-recommended SCIT build-up protocol: 1–2 injections per week for approximately 5 months, tapering to every other week, then monthly by approximately month 10. Blume SW, et al. J Managed Care Spec Pharmacy. 2015;21(11) observed 27.3 visits/year during build-up in practice surveys, likely reflecting real-world adherence patterns including missed appointments. Maintenance visits (16.9/yr) from Blume. Direct medical cost $30.35/visit; 65.2 min total patient time per visit.
- Mao EJ, et al. Cost of SCIT in commercially insured patients: IBM MarketScan analysis of 131,493 patients. Curr Med Res Opin. 2019;35(8). / Bernstein DI, et al. Allergic rhinitis. JAMA. 2024. (~$5,000 for 5-year SCIT course.)
- Sen AP, et al. Site-of-service differential: total payment 145% higher, patient OOP 109% higher in hospital outpatient vs. physician office (102.7M commercial claims). Health Affairs. 2022. / Neprash HT, et al. Mean office visit price $108 higher in HOPD vs. office (MarketScan commercial). JAMA Intern Med. 2015.
- Mendoza J, Carlson G, Nath P, Quinn J. A look at adherence with subcutaneous immunotherapy without out-of-pocket patient costs. Ann Allergy Asthma Immunol. 2023. Military health system, no out-of-pocket cost: only 34% completed 3+ years.
- Kaiser Family Foundation. Employer Health Benefits Survey 2024. Average individual deductible $1,787; HDHP average $2,418.
- Tankersley M, Winders T, Aagren M, Brandi H, Pedersen MH, Loftager ASL, Bøgelund M. Subcutaneous immunotherapy takes more than the time in the clinic. Curr Med Res Opin. 2021;37(11):1925–1931. Survey of 106 adults and 191 caregivers: median 50 minutes per visit including travel and clinic time; median 4 hours of work missed per visit; per-visit direct costs of $10 parking, $9 tolls and $10 other ($29 total). Study funded by ALK.
- Gurgel RK, Baroody FM, Damask CC, et al. Clinical Practice Guideline: Immunotherapy for Inhalant Allergy. Otolaryngol Head Neck Surg. 2024. Reports an adherence range of 7%–97% across the literature (per Senna et al.) and concludes SCIT persistence and adherence are generally poor. Also references a survey of 555 patients who discontinued SCIT, in which 40% cited insufficient insurance coverage of allergen extracts and injection visits as the leading reason, versus ~1.5% citing side effects.
- U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2024. Iowa statewide median hourly wage approximately $22/hr (all occupations). Note: the Des Moines–West Des Moines MSA mean hourly wage is $31.09, making the $22/hr estimate conservative for the local market.
Data presented are derived from peer-reviewed publications and national survey data as cited. Cost estimates represent ranges based on published averages and may not reflect individual patient circumstances. SCIT out-of-pocket estimates incorporate copay, coinsurance, deductible, and facility fee data from multiple sources as noted. Indirect cost estimates use published median values. All Allergenix pricing is current as of 2026 and is available on our pricing page.
A different approach to allergy treatment starts here
Enrollment takes about two minutes. We'll confirm your visit within one business day and send everything you need beforehand.
